Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Multiple Myeloma
  3. NCT06324266

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma Clinical Trial

Official title:
Study on the Efficacy and Safety of Low-dose Cyclophosphamide as Maintenance Therapy for Multiple Myeloma Unsuitable for Transplantation

Clinical Trial Summary

The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable for transplantation in the standard-risk group.

Clinical Trial Description

The investigators will conduct randomized and controlled clinical studies to preliminarily explore the efficacy and safety of low-dose cyclophosphamide in maintenance therapy for MM that is not suitable for transplantation in the standard -risk group. Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy will use cyclophosphamide or lenalidomide as maintain therapy for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06324266
Study type Interventional
Source Jinling Hospital, China
Contact Zhao Qian
Phone 18251835035
Email 540598707@qq.com
Status Recruiting
Phase Phase 2/Phase 3
Start date April 16, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04052880 - Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Phase 2
Active, not recruiting NCT03742297 - Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Phase 3
Not yet recruiting NCT05558319 - NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Phase 3
Recruiting NCT04891809 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Phase 2
Not yet recruiting NCT05561049 - Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
Completed NCT01936532 - Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) Phase 2
Recruiting NCT05259553 - Biomarkers in Multiple Myeloma N/A
Completed NCT01809717 - Multiple Myeloma and Exercise N/A
Withdrawn NCT04348006 - Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Phase 4
Terminated NCT03733691 - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Phase 2
Active, not recruiting NCT00405756 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Phase 3
Recruiting NCT05665140 - Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Phase 2/Phase 3
Not yet recruiting NCT05088330 - A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM N/A
Active, not recruiting NCT03948035 - Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Phase 3
Not yet recruiting NCT06348147 - Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Phase 2